Australian clinical trial site selected to initiate development of novel cancer treatment

Sydney, 23 August 2019 – AUM Biosciences has kicked off its oncology drug development activities. A Phase I Multiple Ascending Dose (MAD) trial for a novel anti-cancer compound, AUM001, a highly specific Mnk1/2 inhibitor, has commenced in Australia. The trial will investigate the safety, tolerability and drug distribution kinetics of different doses of AUM001 and will help determine the optimal dose to take forward into cancer patients. AUM001 is being developed by AUM Biosciences, a Singapore-headquartered, oncology-focused biotechnology company, with a newly launched presence in Australia, that aims to develop innovative and affordable oncology medicines for cancer patients in Asia-Pacific as well as globally.

“Australia was chosen as the first site for clinical development of this important compound, due to the high quality of its clinical researchers and wide acceptability of data generated at Australian sites by global regulatory agencies,” said Vishal Doshi, CEO of AUM Biosciences.

AUM001 has shown potential in a range of solid and haematological tumours and the clinical development program launched in Australia will be critical in investigating the possibility of this therapy becoming an important treatment option in the Asia-Pacific region and globally.

Previously, Phase III trials have made up the largest component of research activities in Australia. However, Phase I clinical trials are now emerging within the Australian market, having grown by 17.2 percent compared with just 1.8 percent globally .

With an advanced research infrastructure and talent, a stable business environment as well as efficient regulatory pathways, Australia is well positioned to be an increasingly international focus for early phase clinical trials. Additionally, Australia’s diverse ethnic make-up, as well as its high compliance with international data standards, ensures diverse and ethical data sets and global acceptability.

“We are optimistic about the possibilities for our Mnk inhibitor, a novel molecule, as a safe and effective option for cancer patients in Australia and beyond. The Mnk inhibitor has the potential to be developed either as a standalone treatment or in combination with other therapies,” said Australian based John Patava, Chief Operating Officer, AUM Biosciences.

About AUM Biosciences

AUM Biosciences is an award-winning, oncology- focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian- prevalent cancers.

AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need. For more information, please visit www.aumbiosciences.com or email info@aumbiosciences.com.

For media enquiries, please contact:

GCI Health on behalf of AUM Biosciences

Rikki Jones | +65 8647 9707 |rikki.jones@gcihealth.com.

Payal Sadhwani | +65 9654 6453 |payal.sadhwani@gcihealth.com.

AUM Biosciences

Devangi Dave | +1 301 529 5470 | devangid@aumbiosciences.com .

REFERENCES

Australian Trade and Investment Commission (AUSTRADE). Clinical Trials. Available at https://www.austrade.gov.au/ArticleDocuments/2814/Clincal-Trials-Capability-Report.pdf.aspx. Last accessed August 2019.